Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dapagliflozin 10 mg Under Fed Conditions
NCT04881006Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Peak Plasma Concentration, Area Under the Curve to Last Timepoint and 1 more. Started Dec 2020; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04881006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04881006.